moclobemide has been researched along with Fatigue Syndrome, Chronic in 3 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic fatigue syndrome is characterized by prolonged and disabling fatigue and a range of neuropsychiatric symptoms including depressed and/or irritable mood." | 2.69 | A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. ( Bennett, BK; Hickie, IB; Lloyd, AR; Wakefield, D; Wilson, AJ; Wright, JM, 2000) |
| " We studied the efficacy and adverse effects of moclobemide in patients with chronic fatigue syndrome, stratifying the sample both by co-morbid major depressive illness and by sleep disturbance." | 2.68 | An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. ( Cleary, KJ; White, PD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hickie, I | 1 |
| Wilson, A | 1 |
| White, PD | 1 |
| Cleary, KJ | 1 |
| Hickie, IB | 1 |
| Wilson, AJ | 1 |
| Wright, JM | 1 |
| Bennett, BK | 1 |
| Wakefield, D | 1 |
| Lloyd, AR | 1 |
2 trials available for moclobemide and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome.
Topics: Adult; Benzamides; Depressive Disorder; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged | 1997 |
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.
Topics: Adult; Comorbidity; Depressive Disorder; Double-Blind Method; Fatigue Syndrome, Chronic; Female; Hum | 2000 |
1 other study available for moclobemide and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
A catecholamine model of fatigue.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Benzamides; Brain; Catecholamines; Depressive D | 1994 |